FDA vs EMA: Medical Device Approval Process Compared

Bringing a medical device to market requires navigating two of the world's most rigorous regulatory systems: the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) framework, which operates alongside the European Commission and Notified Bodies under EU MDR. Understanding the differences between these pathways is not optional — it is a core competency for any manufacturer targeting either market.

This article compares the FDA and EU regulatory systems head-to-head, covering classification logic, submission types, review timelines, and post-market obligations. Whether you are entering the U.S. or EU market first, or pursuing parallel submissions, the details below will help you plan realistically.

Regulatory Frameworks

United States — FDA The FDA regulates medical devices under the Federal Food, Drug, and Cosmetic Act (FD&C Act), primarily through the Center for Devices and Radiological Health (CDRH). The FDA operates as a single national competent authority, meaning all submissions go directly to the FDA, and decisions are made centrally.

European Union — EU MDR / Notified Bodies In Europe, the Medical Device Regulation (EU) 2017/745 (MDR) replaced the Medical Device Directive (MDD) and has been fully applicable since May 2021 (with phased transition periods). Unlike the FDA, the EU does not have a single central reviewer. Instead, independent third-party organizations called Notified Bodies assess device conformity on behalf of the European Commission. This decentralized structure creates variability in assessment timelines and outcomes across Notified Bodies.

Classification Systems

Device classification determines which regulatory pathway applies and how much scrutiny a device receives.

FDA Classification: Class I, II, and III

• Class I: Low risk. Most exempt from 510(k) premarket notification. Subject to General Controls (labeling, registration, listing).
• Class II: Moderate risk. Most require a 510(k) premarket notification, demonstrating substantial equivalence to a legally marketed predicate device. Some Class II devices require a De Novo request if no suitable predicate exists.
• Class III: High risk (life-sustaining or life-supporting). Require a Premarket Approval (PMA), the most rigorous pathway, involving full clinical evidence review.

EU Classification: Rule-Based System The EU uses a rule-based classification system with 4 classes: Class I, IIa, IIb, and III. Classification is determined by applying 22 rules based on the device's intended purpose, invasiveness, duration of contact, and body location affected.

• Class I: Low risk. Manufacturer self-declares conformity. Some Class I devices with measuring function or supplied sterile require Notified Body involvement.
• Class IIa / IIb: Medium risk. Notified Body assessment required.
• Class III: High risk. Full Notified Body audit and technical documentation review.

Comparison Table

Aspect	FDA (US)	EU MDR
Governing body	FDA / CDRH	European Commission + Notified Bodies
Classification basis	Risk + intended use (Class I/II/III)	Rules-based (Class I/IIa/IIb/III)
Primary pathway (moderate risk)	510(k) — substantial equivalence	CE marking — conformity assessment
High-risk pathway	Premarket Approval (PMA)	Notified Body full review (Annex IX/X)
Predicate device concept	Yes — central to 510(k)	No direct equivalent
Clinical evidence standard	Reasonable assurance of safety & effectiveness	Clinical evaluation per MEDDEV 2.7/1 rev. 4
Review timeline (moderate risk)	90 days (standard 510(k)); 30 days (SE)	3–12+ months (varies by Notified Body)
Review timeline (high risk)	180 days (PMA)	12–24+ months
UDI system	FDA UDI — GUDID database	EU UDI — EUDAMED database
Post-market surveillance	MDR/MDV reporting, 522 studies	PMCF, PSUR, periodic safety updates
Single authority	Yes	No — 22+ designated Notified Bodies

Submission Types in Detail

FDA Pathways

510(k) Premarket Notification The 510(k) is the most commonly used pathway for Class II devices. The core concept is substantial equivalence: you must demonstrate that your device is as safe and effective as a legally marketed predicate device already on the market. The 510(k) does not require clinical trials in all cases; bench testing, biocompatibility data, and performance testing often suffice. FDA review is targeted at 90 calendar days.

Premarket Approval (PMA) For Class III devices, the PMA requires valid scientific evidence — typically well-designed clinical investigations — demonstrating reasonable assurance of safety and effectiveness. This is a full application with manufacturing quality data, non-clinical tests, and clinical study reports. PMAs undergo a 180-day review target, though advisory panel meetings often extend the timeline.

De Novo Classification Request When a novel low-to-moderate risk device has no predicate, manufacturers can submit a De Novo request to establish a new classification with special controls. A cleared De Novo decision can then be used as a predicate for future 510(k) submissions.

EU Pathways

CE Marking via Notified Body For Class IIa, IIb, and III devices, manufacturers must engage a Notified Body to conduct a conformity assessment. The Notified Body reviews technical documentation, quality management system (ISO 13485), clinical evaluation reports, and labeling. Upon successful review, the manufacturer receives an EU certificate and can affix the CE mark.

CE Marking Self-Declaration (Class I) Most Class I devices do not require Notified Body involvement. The manufacturer prepares a Declaration of Conformity and technical documentation, self-declaring compliance with the General Safety and Performance Requirements (GSPR) in Annex I of EU MDR.

Predicate Device Concept vs. Essential Requirements

One of the starkest differences between the two systems is how they evaluate device safety.

Under the FDA's 510(k) pathway, the predicate device concept allows manufacturers to demonstrate that their device is substantially equivalent to a device already on the market — inheriting the pre-existing regulatory status of that device. Critics argue this can allow outdated technology standards to persist, though the FDA's 510(k) Safety and Performance Based Pathway aims to address this for certain device types.

The EU system takes a different approach. Under EU MDR, each device must meet the General Safety and Performance Requirements (GSPR) on its own merits, supported by a clinical evaluation that includes clinical data specific to the device (not simply comparison to a predicate). This places a heavier burden on clinical evidence generation, particularly for Class III and implantable devices.

Notified Bodies vs. FDA Direct Review

A key structural difference is who actually reviews your device.

In the U.S., the FDA reviews all submissions directly. This means a consistent, centrally enforced standard — but also a single point of congestion. CDRH manages a large workload and has publicly committed to performance goals under the Medical Device User Fee Amendments (MDUFA).

In the EU, Notified Bodies are private organizations accredited by national authorities (National Accreditation Bodies) and designated by EU member states. There are approximately 40 designated Notified Bodies under EU MDR (far fewer than under the old MDD, which contributed to capacity constraints). Each Notified Body has its own processes, communication style, and assessment depth. Manufacturers should carefully select a Notified Body based on device type expertise, capacity, and geographic reach.

UDI Requirements

Both the FDA and EU MDR require Unique Device Identification (UDI) systems, though the databases and timelines differ.

• FDA UDI: Requires device labelers to submit UDI data to the GUDID (Global Unique Device Identification Database). Labeling requirements have been phased in, with Class I devices now largely covered.
• EU UDI (EUDAMED): EU MDR mandates UDI assignment and registration in the European Database on Medical Devices (EUDAMED). Full EUDAMED functionality has been phased across device classes, with Class III devices required first.

Post-Market Requirements

Both regulatory systems have strengthened post-market surveillance requirements significantly in recent years.

FDA post-market obligations include Medical Device Reporting (MDR) for adverse events and malfunctions, corrections and removals reporting, and 522 post-market surveillance studies for certain devices. The FDA also conducts facility inspections.

EU MDR post-market obligations under EU MDR are notably more extensive than the prior MDD. Manufacturers must now maintain a Post-Market Clinical Follow-Up (PMCF) plan and report, a Periodic Safety Update Report (PSUR) (annually for Class IIb/III, every two years for Class IIa), and a Summary of Safety and Clinical Performance (SSCP) for Class III and implantables, which is publicly accessible via EUDAMED.

Strategic Considerations

For manufacturers targeting both markets, a few strategic points are worth noting:

1. Start with clinical evidence early. EU MDR's clinical evidence requirements are extensive. Building a robust clinical evaluation plan from the outset — rather than retrofitting it — saves time and cost.
2. Predicate selection is critical for 510(k). The choice of predicate affects testing requirements, intended use scope, and future regulatory flexibility. A weak or remote predicate creates 510(k) deficiency risk.
3. Notified Body capacity is constrained. The reduction in designated Notified Bodies post-MDR has created backlogs. Engage your Notified Body early, ideally during product development.
4. UDI systems are not fully harmonized. Despite similar goals, FDA GUDID and EU EUDAMED have different data requirements, submission formats, and timing rules. Plan for separate UDI workflows.

Conclusion

The FDA and EU regulatory pathways both aim to ensure that medical devices are safe and effective, but they take meaningfully different approaches to achieving that goal. The FDA relies on a centralized review with the pragmatic predicate concept; the EU relies on decentralized Notified Body assessment with demanding clinical evidence standards. Neither system is uniformly faster or easier — the right strategy depends on your device classification, clinical data status, and target market timeline.

---

Keeping pace with regulatory changes across both the FDA and EU — and 25 other jurisdictions worldwide — is a full-time challenge. MedFlux monitors 27 regulators in real time, delivering curated intelligence on guidance updates, classification changes, and new submission requirements directly to your team. Never miss a regulatory change that affects your product portfolio.